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Abstract
Background: Patients who participate in clinical trials may experience better clinical outcomes than patients who initiate
similar therapy within clinical care (trial effect), but no published studies have evaluated a trial effect in HIV clinical trials.
Methods: To examine a trial effect we compared virologic suppression (VS) among patients who initiated HAART in a clinical
trial versus in routine clinical care. VS was defined as a plasma HIV RNA #400 copies/ml at six months after HAART initiation
and was assessed within strata of early (1996–99) or current (2000–06) HAART periods. Risk ratios (RR) were estimated using
binomial models.
Results: Of 738 persons initiating HAART, 30.6% were women, 61.7% were black, 30% initiated therapy in a clinical trial and
67% (n=496) had an evaluable six month HIV RNA result. HAART regimens differed between the early and current periods
(p,0.001); unboosted PI regimens (55.6%) were more common in the early and NNRTI regimens (46.4%) were more
common in the current period. Overall, 78% (95%CI 74, 82%) of patients achieved VS and trial participants were 16% more
likely to achieve VS (unadjusted RR 1.16, 95%CI 1.06, 1.27). Comparing trial to non-trial participants, VS differed by study
period. In the early period, trial participants initiating HAART were significantly more likely to achieve VS than non-trial
participants (adjusted RR 1.33; 95%CI 1.15, 1.54), but not in the current period (adjusted RR 0.98; 95%CI 0.87, 1.11).
Conclusions: A clear clinical trial effect on suppression of HIV replication was observed in the early HAART period but not in
the current period.
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Introduction
A trial effect occurs when study participants experience a benefit
merely by the act of trial participation. The effect may arise due to
a treatment effect (newer, better or experimental treatments
available to trial participants but unavailable outside the trial), a
protocol effect (differences in the way treatment regimens are
delivered), a care effect (differences in care), a Hawthorne effect
(behavior change secondary to being under observation) or a
placebo effect (‘‘psychologically mediated’’ benefits that arise due
to being in a trial) [1–4]. A trial effect should be distinguished from
apparent effects (biases) particularly selection bias (differences
between trial and non-trial participants).
The evidence for or against a trial participation benefit or trial
effect is inconclusive [1,3,5–7]. Current evidence, derived
primarily from cancer trials, is limited in breadth, quality and
quantity. HIV-related clinical trials provide an excellent substrate
for the measurement of a trial effect. HIV infection is a chronic
illness with well-characterized treatments and HIV-related out-
comes are easily measured and clinically meaningful.
To determine whether a trial effect exists in HIV clinical trials,
we compared virologic suppression (VS) between HIV-infected
patients who were antiretroviral naı ¨ve and who initiated highly
active antiretroviral therapy (HAART) either in a trial or as part of
routine medical care. The benefit of HAART to patients is
unquestionable. However, if participation in clinical trials leads to
a beneficial trial effect, careful consideration of the mechanisms
and consequences of that trial effect would be needed. At the least,
aspects of the trial effect, such as protocol effect or care effect, may
need to be incorporated into clinical care to achieve similar results.
Furthermore, the existence of a positive trial effect might suggest
reduced generalizability of clinical trials data to non-trial
participants. Finally, clinical trials data provide evidence for the
care and treatment guidelines of HIV infected persons and a trial
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21824effect might oblige guidelines to caution about possible differences
in outcome in non-trial settings.
Methods
Study design
We conducted a secondary data analysis using the University of
North Carolina (UNC) Center for AIDS Research (CFAR) HIV/
AIDS clinical cohort (UCHCC). This cohort, comprising adult
($18 years) HIV-infected persons who receive health care at the
UNC Hospital Infectious Diseases (ID) clinic, has been described
previously [8,9]. Over 95% of the UNC ID clinic population has
consented to participate in the UCHCC and non-consenting
patients do not differ significantly from those who provide consent.
All patients provided written informed consent, and the study was
approved by the Biomedical Institutional Review Board of the
University of North Carolina at Chapel Hill.
Study population
Antiretroviral naı ¨ve HIV-infected adults who initiated HAART
from April 1996 to December 2006 were included in this analysis.
HAART was defined as any combination of three or more
antiretroviral agents, or a combination of at least one protease
inhibitor (PI) plus one non nucleoside reverse transcriptase
inhibitor (NNRTI) with or without additional agents. Patients
were characterized as trial participants if HAART was initiated as
part of a clinical trial. Patients co-infected with HCV and/or HBV
were included in the analysis. Clinical trials included NIH AIDS
Clinical Trial Group (ACTG) supported or industry sponsored
trials.
Variable Specification
We defined the outcome of virologic suppression (VS) as having
a plasma HIV RNA level #400 copies/mL at six months from the
date of HAART initiation, using a window of five to nine months
and selecting the plasma HIV RNA value nearest six months if
more than one value occurred in this window. We considered trial
participation as the factor of interest.
A joint categorization of gender (male/female) and sexual
orientation (heterosexual/homosexual/bisexual) resulted in a
variable with three categories 1) men who have sex with men
(MSM) 2) heterosexual men and 3) women. Bisexual men were
placed in the MSM category. Additional variables included
insurance status (Medicaid/Medicare, none and private/other),
distance traveled from home to the UNC Infectious Diseases (ID)
clinic in miles, and the duration in month’s from the date of HIV
diagnosis to HAART initiation.
Selected clinical laboratory values that may influence trial
participation, initiation of HAART and treatment outcome
including baseline CD4 cell count, plasma HIV RNA level,
hemoglobin, creatinine, alanine aminotransferase [ALT], and
absolute neutrophil count [ANC] were assessed. For laboratory
results not available at baseline an extended window spanning 180
days before and up to 14 days after the date HAART was initiated
was considered. ALT, ANC, creatinine and hemoglobin were
categorized as normal or abnormal using gender appropriate
normal ranges.
Treatment characteristics included the type of HAART and the
date HAART was initiated. HAART was categorized as 1) a
ritonavir-boosted protease inhibitor (PI) or two PIs combined with
either two or three nucleoside reverse transcriptase inhibitors
(NRTIs) 2) a NNRTI combined with either two or three NRTIs 3)
an unboosted PI combined with either two or three NRTIs 4) a
NNRTI and a PI with or without NRTIs and 5) three NRTIs. The
year HAART was initiated was dichotomized to represent the
differences in initial treatment regimens as the early HAART
period (1996-99) and the current HAART period (2000-06) [10].
Statistical Analyses
Baseline differences in demographic, clinical, treatment and
laboratory characteristics were explored using the chi square test, t
test and Wilcoxon rank sum test with 2-sided P values reported in
all cases.
We estimated an unadjusted risk ratio (RR) and a 95%
Confidence Interval (CI), to assess the relationship between trial
participation and the risk of VS at six months after HAART
initiation. Multivariable analyses were performed using Poisson
regression with no offset and a robust variance estimator to
provide an estimate of the risk ratio [11–13]. We assessed effect
measure modification with interaction terms between relevant
covariates. Effect measure modification was considered to be
present if the coefficient estimate for the interaction term differed
significantly from zero (a=0.1). A significant interaction was
noted between trial participation and the period in which HAART
was initiated. Therefore all analyses were stratified by HAART
period.
Confounding was evaluated by both substantive (a priori) and
change in estimate criteria. We used a manual backward
elimination procedure to arrive at the final model. A covariate
was retained as a confounding variable if it changed the effect
estimate by at least 10 percent. Two variables ‘type of HAART’
and ‘CD4 cell count’ did not change the effect estimate by $10%
but were included in the final model based on substantive
knowledge.
Sensitivity Analyses
Our primary analysis involved a complete case analysis. HIV
RNA result at the six month time point was unavailable for 33% of
patients. We completed sensitivity analyses to explore the potential
impact of the missing data. We conducted an extreme case analysis
to obtain the upper and lower bounds of the RR [14–16]. For this
we assumed that among the patients with missing outcome, every
trial participant achieved virologic success while non-trial
participants were virologic failures and vice versa. A second
analysis assigned virologic failure to all or a varying fraction of
missing values for trial and non-trial participants [14–16].
Intercooled Stata (version 9.0), Stata Corporation, (College
Station, TX) was used for all analyses.
Results
Sample Characteristics
Of the 738 ARV naı ¨ve persons initiating HAART, 67%
(n=496) had an HIV RNA result available at six months. Results
for this group (complete cases) are presented here (Table 1). The
mean age of patients was 38.5 years (standard deviation 9.9),
37.3% were women, 60.1% were black, 27.4% were white, 8.3%
were Hispanic and 34% initiated therapy in the context of a
clinical trial. Trial participants were more likely to be MSM
(42.3%), non Black (41.4%) and not have insurance (42.9%)
(p,0.05). Compared to non-trial participants (14.4%) fewer trial
participants (8.3%) reported injection drug use. No significant
between group differences were observed in baseline HIV RNA
level or CD4 cell count. Trial participants were slightly more likely
to have a viral load (VL) at or close to the 6 month time point.
However, the distribution around the 6 month time point was
similar in that similar proportions had VL before and after 6
months in the two treatment groups (trial and non-trial).
Is There a Trial Effect in HIV Clinical Trials?
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e21824Table 1. Baseline sample characteristics for study population, complete cases and comparing trial to non-trial participants
restricted to complete cases.
Study Population Complete Cases
Non-Trial
Participants Trial Participants p value*
N=738 % N=496 % N=327 % N=169 %
Demographic and Behavioral Characteristics
Age (years)
,40 429 58.1 273 55 183 56 93 53.3 0.6
Gender/sexual preference
MSM
1/Bisexual men 252 34.2 175 35.3 101 30.9 74 43.8 0.02
Heterosexual men 260 35.2 165 33.2 114 34.9 51 30.2
Heterosexual women 226 30.6 156 31.5 112 34.2 44 26.0
Race
Black 455 61.7 298 60.1 211 64.5 87 51.5 0.005
Non Black
2 283 38.3 198 39.9 116 35.5 82 48.5
Access to Care Characteristics
Insurance Status
Public
3 191 26.3 126 25.9 103 31.8 23 14.1 0.001
None 276 38.1 168 34.6 96 29.7 72 44.2
Private/Other 258 35.6 192 39.5 124 38.4 68 41.7
Distance to ID
4 clinic (miles)
,50 182 24.7 130 26.3 77 23.6 53 31.4 0.06
.50 527 71.3 365 73.7 249 76.4 116 68.6
Clinical Characteristics
CD4 cells/uL
#200 321 56.6 257 57.6 151 54.1 106 63.4 0.1
.200–350 107 18.9 81 18.2 53 19.0 28 16.8
.350 139 24.5 108 24.2 75 26.9 33 19.8
Mean HIV RNA (log10) (sd) 4.7 (1.0) 4.9 (1.0) 4.7 (1.0) 4.8 (1.0) 0.6
Diagnosis to treatment (months)
#3 250 38.9 168 37.4 116 37.2 52 38.0 0.9
.3 393 61.1 281 62.6 196 62.8 85 62.0
Treatment Characteristics
HAART Initiation Year
1996-99 266 36.0 161 32.5 124 37.9 37 21.9 0.001
2000-06 472 64.0 335 67.5 203 62.1 132 78.1
HAART category
5
2 or 3 NRTI plus PI/r or 2 PI 128 17.4 99 20.0 39 11.9 60 35.5 0.001
2 or 3 NRTI plus NNRTI 288 39.0 192 38.7 132 40.4 60 35.5
2 or 3 NRTI plus PI (unboosted) 218 29.5 134 27.0 116 35.4 18 10.7
NNRTI/PI +/2 2 NRTI 55 7.5 40 8.1 20 6.1 20 11.8





Normal 348 47.2 268 62.2 173 65.3 95 57.2 0.09
Abnormal 221 30.0 163 37.8 92 34.7 71 42.8
Hemoglobin (g/dL)
Normal 258 34.9 195 41.1 116 43.6 79 47.6 0.4
Abnormal 311 42.1 237 54.9 150 56.4 87 52.4
Creatinine (mg/dL)
Normal 685 93.1 462 93.2 298 91.1 164 97 0.01
Abnormal 51 6.9 34 6.8 29 8.9 5 3.0
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Patients participated in 13 different clinical trials, nine
sponsored by the AIDS Clinical Trials Group (ACTG) and four
by pharmaceutical companies (Table 2)[17–30]. All but two of the
trials were Phase III or IV. Two ACTG trials and one industry
sponsored trial enrolled patients in the early period, and seven
ACTG and three industry sponsored trials enrolled patients in the
current HAART period.
HAART Regimens
The composition of HAART regimens significantly differed
between trial and non-trial participants (p=0.001). Trial partic-
ipants were more likely to be initiated on a boosted PI regimen
(60.6%) while non-trial participants were more likely to be
initiated on an NNRTI based regimen (68.8%) (p=0.001). Most
patients initiating an NNRTI regimen received efavirenz (85%)
while the majority of those initiating a boosted PI regimen
received lopinavir/ritonavir (70.8%). Of the 134 patients who
received unboosted PI regimens, 64% were initiated on nelfinavir.
The most commonly used nucleoside/nucleotide backbone was
lamivudine/zidovudine (49.7%), followed by lamivudine/stavu-
dine (14.7%), tenofovir/emtricitabine or lamivudine (13.8%), and
lamivudine/abacavir (7%).
In both the early and current periods, HAART regimens
differed between trial and non-trial participants with more trial
participants initiating boosted PI regimens and more non-trial
participants initiating NNRTI based regimens (P,0.05) (Figure 1).
Effect of trial participation on virologic suppression
Overall, 78% of patients achieved VS (95%CI 74, 82). Trial
participants were 16% more likely to achieve VS when compared
to non-trial participants (RR 1.16, 95%CI 1.06, 1.27). However
the magnitude of this difference was dependent on the period in
which HAART was initiated (early versus current). We thus
present our results stratified by HAART period.
The effect of trial participation on VS differed by the period in
which HAART was initiated (p=0.001). In the early period, more
trial participants achieved VS than non-trial participants (RR
1.42; 95%CI 1.24, 1.54). Although a difference was also observed
in the current period, it was smaller and not statistically significant
(RR 1.07; 95%CI 0.95, 1.19) (Table 3). After adjustment for age,
distance traveled to receive care at UNC ID clinic, baseline HIV
RNA levels, CD4 cell count, months from HIV diagnosis to
HAART initiation, creatinine and type of HAART, trial
participants remained more likely to achieve virologic suppression
than non-trial participants (RR 1.33; 95% CI 1.15, 1.54) in the
early period. By contrast, in the current period, virologic
suppression of trial and non-trial participants was similar (RR
0.98; 95% CI 0.87, 1.11).
Missing Data and Sensitivity Analyses
The outcome of VS measured by an HIV RNA result within the
specified 5-9 month window was unavailable for 242 (33%)
patients. More non-trial participants (36.4%) had missing data
than trial participants (24.6%) (p,0.05). Patients with missing
HIV RNA results were similar to those with values in terms of age
(mean age 37 vs. 39 years), race (65% vs. 60% black) and gender
(29% vs. 31% female). Likewise, we found no differences in clinical
characteristics (baseline HIV RNA and CD4 cell count) and
laboratory parameters (ALT, ANC, hemoglobin) (all p values
.0.05). However, more patients missing HIV RNA results were
uninsured (45.2% vs. 34.6%) and fewer had private insurance
(27.6% vs.39.5%) (p=0.004).
The proportion of patients experiencing virologic success or
failure in each group or time period is not known and any
assumption, including the primary analysis, has some bias.
Therefore we performed a series of sensitivity analyses, in which
the proportion of virologic successes and failures in patients with
missing data were varied, including a missing equals failure
(M=F) analysis (Figure 2). In the early period, all but one of the
sensitivity analyses performed provided statistically significant risk
ratios favoring trial participation. In the current period, of nine
different sensitivity analyses (including the M=F analysis), trial
participation was only favored in one extreme case analysis in
which all trial participants with missing outcomes were considered
virologic successes while non-trial participants were virologic
failures (aRR 1.36, 95%CI 1.18, 1.55) (Figure 2).
Discussion
This study is the first to examine a trial effect in HIV clinical
trials by comparing virologic suppression (VS) among antiretro-
viral (ARV) naı ¨ve trial and non-trial participants initiating
HAART. Close to two-thirds of treatment naive patients achieved
virologic suppression six months after initiating HAART. The
effect of trial participation varied by the period of HAART
initiation. In the early HAART period (1996-99), trial participants
achieved VS more commonly than non-trial participants.
Study Population Complete Cases
Non-Trial
Participants Trial Participants p value*
N=738 % N=496 % N=327 % N=169 %
7ALT U/L
Normal 451 61.1 338 81.1 204 81.3 134 80.7 0.9
Abnormal 100 13.6 79 18.9 47 18.7 32 19.3
*p value comparing trial to non trial participants restricted to complete cases.
1MSM=Men who have sex with Men;
2Non Black includes Caucasian, Hispanic and Other race.
3Public insurance= Medicaid/Medicare;
4ID= University of North Carolina Infectious Disease.
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difference in VS comparing trial to non-trial participants. Our
observations were supported by the sensitivity analyses.
There may be several reasons why a trial effect was readily
apparent in the early HAART period. Results from cancer trials
have suggested a trial effect in trials conducted before 1986, a time
of rapid change for cancer care and treatments[3]. This might also
be the case in our study where during the early period, there were
differences in the type of HAART with more trial participants
initiated on an NNRTI/PI or boosted PI combination and fewer
initiated on an unboosted PI regimen (i.e., a treatment effect).
However, even after controlling for differences in the type of
HAART, the beneficial effect of trial participation in the early
period persisted. Treatment regimens during this period were
complex and associated with fairly significant side effects.
Therefore, it is possible that trial participants benefited from both
a care effect and a protocol effect resulting in better treatment
outcomes. Furthermore, in the early period, HIV infection was
associated with considerable morbidity and mortality which likely
influenced patient’s attitudes towards HAART. We hypothesize
that, in part, the high proportion of VS experienced by trial
participants resulted from a synergy between patient attitudes and
care effect.
We believe our results demonstrate a true trial effect as we were
able to address the challenge of identifying an optimal comparison
group. Such a comparator group might comprise trial eligible
subjects who declined trial participation but were similar in other
baseline characteristics [3,5]. Although we are unable to state that
non-trial participants were either trial eligible or were trial eligible
refusers our data suggests that our two groups were comparable.
First, both trial and non-trial participants were drawn from a
single clinic population suggesting similarity between groups.
Second, we increased between group homogeneity by restricting
our study population to include only ARV naı ¨ve subjects. Third,
Table 2. Details of Clinical Trials included in this study: Number of Patients, Study Design and Study Title.
Study N % Study Design Study Title
ACTG 384 25 14.8 Treatment, Double-Blind, Pharmacokinetics Study Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor
With Dual Nucleosides in Initial Therapy of HIV Infection
ACTG 388 6 3.6 Treatment, Open Label, Safety Study A Phase III Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in
Combination With Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and
Indinavir (IDV) in HIV-Infected Subjects With Less Than or Equal to 200 CD4 Cells/
mm3 or Greater Than or Equal to 80,000 HIV RNA Copies/Ml in Plasma
ACTG 5015 5 3.0 Treatment, Efficacy Study A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two
Age-Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of
Accelerated HIV-Disease Progression Associated With Aging
ACTG 5073 6 3.6 Treatment, Randomized, Open Label, Uncontrolled,
Parallel Assignment, Safety/Efficacy Study
A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily
Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and
Therapy Administered Under Direct Observation
ACTG 5095 35 20.7 Treatment, Active Control, Safety/Efficacy Study Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-
Sparing Regimens for the Initial Treatment of HIV Infection
ACTG 5142 21 12.4 Treatment, Randomized, Open Label, Active
Control, Parallel Assignment, Safety/Efficacy Study
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus
Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as
Initial Therapy for HIV-1 Infection
ACTG 5164 16 9.5 Diagnostic, Randomized, Open Label, Active
Control, Parallel Assignment, Efficacy Study
A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With
Acute Opportunistic Infections: Immediate Versus Deferred Initiation of
Antiretroviral Therapy
ACTG 5175 7 4.1 Treatment, Randomized, Open Label, Active
Control, Parallel Assignment, Efficacy Study
A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of
Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase
Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected
Individuals From Resource-Limited Settings (PEARLS) Trial
ACTG 5202 28 16.6 Other, Randomized, Active Control, Parallel
Assignment, Safety/Efficacy Study
A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir
in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or
Abacavir/Lamivudine in Antiretroviral-Naive Subjects
Abbott M97 7 4.1 Treatment, Randomized, Double Blind (Subject,
Caregiver, Investigator, Outcomes Assessor),
Parallel Assignment, Safety/Efficacy Study
Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase
Inhibitors in Antiretroviral Naive HIV-Infected Patients
Gilead 903 7 4.1 Treatment, Parallel Assignment A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of
Antiretroviral-Naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil
Fumarate Administered in Combination With Lamivudine and Efavirenz Versus
Stavudine, Lamivudine, and Efavirenz
Gilead 934 1 0.5 Treatment, Randomized, Open Label, Active
Control, Parallel Assignment, Safety/Efficacy Study
Phase 3/Randomized/Open-Label Study of the Treatment of Antiretroviral-Naive
HIV-1-Infected Subjects Comparing Tenofovir Disoproxil Fumarate and
Emtricitabine in Combination With Efavirenz vs. Combivir (Lamivudine/Zidovudine)
and Efavirenz
KLEAN 5 3.0 Treatment, Randomized, Open Label, Dose
Comparison, Parallel Assignment, Safety/Efficacy
Study
A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy
of GW433908 (700 mg BID) Plus Ritonavir (100 mg BID) Versus Lopinavir/Ritonavir
(400 mg/100 mg BID) When Administered in Combination With the Abacavir/
Lamivudine (600 mg/300 mg) Fixed-Dose Combination Tablet QD in Antiretroviral-
Naive HIV-1 Infected Adults Over 48 Weeks
doi:10.1371/journal.pone.0021824.t002
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of HAART and by categorizing the periods in which HAART was
initiated. Finally, we examined detailed baseline demographic and
clinical characteristics, as well as laboratory parameters and found
no substantial differences between these two groups. Consequently
it is highly likely that most of our non-trial participants were trial
eligible and that some proportion ofthem were trialeligiblerefusers.
We found no strong evidence supporting a trial effect in the
current HAART period. Compared to the early HAART period,
the proportion of non-trial participants who achieved VS
increased, but we also noted a decrease in the proportion of trial
participants who achieved this milestone. The enhanced treatment
response in non-trial participants may be due to noteworthy
improvements in ARV therapy between the early and current
Figure 1. Antiretroviral treatment by trial participation.
doi:10.1371/journal.pone.0021824.g001
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combination therapy have reported chronological improvements
in VS [10,31]. Like other studies, we observed changes in the
initial HAART regimen with a significant increase in the use of a
boosted PI or NNRTI and a decline in the use of an unboosted PI
[10]. The superiority of a NNRTI or boosted PI versus unboosted
PI regimens in ARV naı ¨ve persons has been clearly demonstrated
[19,32–33]. Other improvements to ARV therapy include ease of
use (dosing frequency and pill burden), better tolerability and
lower toxicity. Moreover, calendar time may also be associated
with other unmeasured factors such as provider experience,
medication adherence and increased patient awareness about the
benefits of and improvements to HAART. The period in which
HAART was initiated likely acted as a surrogate for these
temporal factors.
The improvements to ARV therapy in the current period may
have lessened the impact of the care effect for trial participants.
Additionally, in the current period HIV infection began to be
regarded as a chronic but treatable infection which may have
influenced patient attitudes. Thus the potential interaction
between care effect and patient attitudes was likely diminished
resulting in a more modest response to treatment among trial
participants. Moreover, in the current period the motivation for
participation in clinical trials may have changed with more
patients choosing clinical trials for objective (e.g. financial) and
subjective (e.g. trust in providers) reasons that we were unable to
measure and which may have decreased the likelihood of success.
Our definition of VS (plasma HIV RNA #400 copies/ml at six
months) may have limited our ability to detect a trial effect in the
current period. A care effect may have needed a longer duration to
become apparent in the current period as, over time, the risk for
non-adherence increases and the structure of a clinical trial may
improve adherence to ARV therapy and to care. Possibly, a longer
outcome period might have favored trial participants and
supported a trial effect. In the current period, all but one of the
trials included in our study was a Phase III or later trial therefore
we feel that these results are most applicable to Phase III or later
trials.
Since this study was conducted at a single center these results
may not be demonstrable in other settings. In our center as
clinicians and clinical trial investigators overlap or are in very close
contact clinical practice may be influenced by the ongoing trials.
One third of our cohort was missing the outcome of VS at the six
month time point. Reassuringly, patients with missing data were
similar to those for whom complete data was available. Results of
sensitivity analyses conducted to determine the potential influence
Figure 2. Sensitivity Analyis: Risk Ratios for viral suppression following different adjustment schema for missing data.
doi:10.1371/journal.pone.0021824.g002
Table 3. Risk Ratios for virologic suppression by trial
participation within strata of HAART period.
Risk Ratios (95% Confidence Intervals)
Unadjusted Adjusted**
Early HAART period (1996-99)
Non-Trial Participants 1 1
Trial Participants 1.42 (1.24, 1.62) 1.33 (1.15, 1.54)
Current HAART period (2000-06)
Non-Trial Participants 1 1
Trial Participants 1.07 (0.95, 1.19) 0.98 (0.87, 1.11)
**adjusted for age, distance traveled to receive care at UNC ID clinic, baseline
HIV RNA levels, CD4 cell count, months from HIV diagnosis to HAART initiation,
creatinine, type of HAART.
doi:10.1371/journal.pone.0021824.t003
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and suggest that the observed effects, or lack thereof, are unlikely
to be attributable to missing data. Potential sources of bias,
including unmeasured confounders, could either mask or inflate a
trial effect [34,35]. We defined VS based on a single measurement,
to minimize bias due to possible differences in measurement
frequency between trial and non-trial participants. In our study,
care setting bias and clinician selection bias appear less likely since
all patients were followed at the UNC Infectious Disease Clinic
and received their health care from a single group of clinicians
[1,3].
We believe this is the first study to clearly and rigorously
demonstrate a trial effect in HIV clinical trials. This observation is
extremely important for later lines of ARV therapy (e.g. salvage
therapy) which are more complex and where the trial effect that
we observed in the early HAART period might still occur due to
the interplay between patient attitudes, protocol effect and care
effect. Also important is the lack of strong support for a trial effect
in the current period. This has significant public health
implications as it demonstrates that HAART achieves comparable
VS both in clinical trials and routine clinical care. These results
suggest that in the current period the efficacy of HAART is no
different from the effectiveness indicating that the results of clinical
trials for treatment naı ¨ve HIV infected patients are generalizable
to the larger population. Clinicians and public health officials can
have confidence that treatment guidelines that are formulated
based on clinical trials data are relevant to routine clinical care and
can be extrapolated to clinical care.
Although, we found no strong evidence for a trial effect in the
current period, there can be advantages to participation in clinical
trials including access to newer treatments, and clinical monitoring
by a dedicated team of study personnel. In keeping with other
studies, we did not observe worse outcomes for trial participants in
either period [36–40]. Therefore, we feel, a reasonable corollary is
that participation in HIV treatment trials does not increase the risk
of an adverse outcome. Most studies do not refute that there is a
positive benefit to trial participation, though the magnitude of the
benefit may differ and may depend on the type of trial [1,41,42].
Lastly, there is an inherent altruism involved in trial participation
which may afford patients a sense of pride and self worth [43–46].
In summary, we demonstrated, for the first time, that
participation in HIV clinical trials resulted in an improved
outcome compared to clinic-based treatment (i.e. trial effect), in
ARV treatment naı ¨ve patients drawn from the same population,
even after controlling for multiple potential confounders. This trial
effect, however, was only observed in the early HAART period
and we found no strong evidence for a trial effect in HIV clinical
trials in treatment naı ¨ve patients in the current HAART period.
This lack of a trial effect in the current HAART period argues that
for studies of combination ARV therapy in treatment naı ¨ve
individuals the efficacy demonstrated in clinical trials is likely to
predict the effectiveness of the therapy in broader treatment
populations.
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